“Desitin is proud to have contributed to the ongoing clinical development of sulthiame, an investigational compound with compelling Phase 2 efficacy data and a favourable safety profile,” said Philipp Bloching, MD, Chief Executive Officer of Desitin. “Sulthiame is now in the best possible hands to successfully complete its development and bring benefits to patients with OSA (obstructive sleep apnea) and other sleep-related breathing indications around the world.”

For more details, please see the official press release.